ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ALLO vs AUTL // EV/EBITDA & P/E VALUATION

Allogene Therapeutics Inc. (NASDAQ) VS. Autolus Therapeutics plc (NASDAQ) • 15-METRIC TALLY: ALLO 1 — AUTL 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALLO VS. AUTL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ALLO AUTL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — -27.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 29.3 36.6 -7.29 AUTL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $431.9M $420.5M $11.3M ALLO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ALLO REV AUTL REV ALLO GROSS % AUTL GROSS % ALLO FCF AUTL FCF
FY 2025 $0 $75.4M — -27.8% -$149.6M -$302.6M
FY 2024 $22.0K $10.1M — -12.5% -$201.0M -$228.3M
FY 2023 $95.0K $1.7M — — -$237.7M -$145.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALLO // BETA —
AUTL // BETA —